{"id":"atorvastatin-ezetimibe","safety":{"commonSideEffects":[{"rate":null,"effect":"Myalgia (muscle pain)"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Gastrointestinal upset"}]},"_chembl":{"chemblId":"CHEMBL1487","moleculeType":"Small molecule","molecularWeight":"558.65"},"_dailymed":{"setId":"6375eae7-e159-4fb2-a91c-9aa20ac3c9e1","title":"LYPQOZET ((EZETIMIBE AND ATORVASTATIN)) TABLET [ALTHERA PHARMACEUTICALS, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atorvastatin is a statin that reduces cholesterol synthesis in the liver by inhibiting the rate-limiting enzyme HMG-CoA reductase, thereby decreasing LDL cholesterol and triglycerides. Ezetimibe selectively inhibits cholesterol absorption in the small intestine by blocking the Niemann-Pick C1-like 1 (NPC1L1) transporter. Together, they provide complementary mechanisms to achieve greater LDL reduction than either agent alone.","oneSentence":"Atorvastatin inhibits HMG-CoA reductase to lower LDL cholesterol, while ezetimibe blocks intestinal cholesterol absorption, providing dual lipid-lowering action.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:30.659Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Cardiovascular disease risk reduction"}]},"trialDetails":[{"nctId":"NCT07489183","phase":"","title":"A Prospective, Open, Observational Study to Confirm the Lipid-lowering Effect, Changes in Glucose Metabolism, and Safety After 6 Months of Administration of Atostazet to Hypercholesterolemic Patients 65 Years of Age or Older","status":"COMPLETED","sponsor":"Dong Wha Pharmaceutical Co. Ltd.","startDate":"2021-08-23","conditions":"Hypercholesterolemia","enrollment":641},{"nctId":"NCT07474649","phase":"PHASE3","title":"A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events","status":"NOT_YET_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2026-06-01","conditions":"Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia","enrollment":103},{"nctId":"NCT04862260","phase":"EARLY_PHASE1","title":"Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2021-10-04","conditions":"Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer","enrollment":3},{"nctId":"NCT07359105","phase":"NA","title":"Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)","status":"RECRUITING","sponsor":"Sin Gon Kim","startDate":"2026-03-09","conditions":"Dyslipidemia Associated With Type II Diabetes Mellitus","enrollment":2186},{"nctId":"NCT06686615","phase":"","title":"A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia","status":"RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2025-02-12","conditions":"Primary Hypercholesterolemiia, Mixed Dyslipidemia","enrollment":2000},{"nctId":"NCT07268625","phase":"PHASE1","title":"Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-12-09","conditions":"Healthy Subjects","enrollment":58},{"nctId":"NCT07235189","phase":"PHASE1","title":"A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-10-28","conditions":"Healthy Subjects","enrollment":58},{"nctId":"NCT05462262","phase":"NA","title":"Intensive Lipid-lowering for Plaque and Major Adverse Cardiovascular Events in Low to Intermediate 10-year ASCVD Risk Population","status":"ENROLLING_BY_INVITATION","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2022-10-10","conditions":"Coronary Artery Disease Progression","enrollment":2900},{"nctId":"NCT07307989","phase":"PHASE2","title":"Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-08-01","conditions":"Ischemic Stroke, Hypercholesteremia","enrollment":300},{"nctId":"NCT06501443","phase":"PHASE4","title":"LATAM LOWERS LDL-C","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-11","conditions":"Hypercholesterolaemia","enrollment":520},{"nctId":"NCT05641753","phase":"PHASE4","title":"Cholesterol Lowering and Residual Risk in Diabetes, Type 1","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-12-06","conditions":"Type 1 Diabetes","enrollment":125},{"nctId":"NCT06896708","phase":"NA","title":"Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome","status":"RECRUITING","sponsor":"Liu yong","startDate":"2025-08-12","conditions":"Chronic Coronary Syndrome","enrollment":766},{"nctId":"NCT05910476","phase":"PHASE4","title":"Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yonsei University","startDate":"2023-05-03","conditions":"Coronary Artery Disease, Dyslipidemias","enrollment":200},{"nctId":"NCT04626973","phase":"NA","title":"Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2021-01-15","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":3048},{"nctId":"NCT05559606","phase":"","title":"An OS to Evaluate the Safety & Efficacy of Fixed Dose Combination Therapy With Atorvastatin and Ezetimibe","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2022-09-07","conditions":"Primary Hypercholesterolemia","enrollment":1839},{"nctId":"NCT05761444","phase":"PHASE4","title":"Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2023-07-26","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":137},{"nctId":"NCT07083206","phase":"","title":"A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin/ Ezetimibe","status":"RECRUITING","sponsor":"Ahn-Gook Pharmaceuticals Co.,Ltd","startDate":"2025-07-29","conditions":"Hypercholesterolemia, Dyslipidemias","enrollment":4500},{"nctId":"NCT06858332","phase":"","title":"Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-15","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":2382},{"nctId":"NCT06789432","phase":"PHASE4","title":"Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population","status":"RECRUITING","sponsor":"Dr. Md. Alimur Reza","startDate":"2025-02-01","conditions":"Hyperlipidemia (E.G., Hypercholesterolemia)","enrollment":500},{"nctId":"NCT07036991","phase":"PHASE4","title":"Clinical Trial of PCSK9 Inhibitor and Statin Treatment for Carotid Artery Stenosis","status":"NOT_YET_RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-07-30","conditions":"Carotid Artery Stenosis","enrollment":406},{"nctId":"NCT06866509","phase":"","title":"To Investigate Blood Lipid Changes and Safety After Litorvazet® Tablets in Dyslipidemia Patients","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-02-28","conditions":"Dyslipidemia","enrollment":3000},{"nctId":"NCT05368545","phase":"NA","title":"Influence of Lipid Lowering on Impaired Coronary Flow","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2020-05-15","conditions":"Coronary Artery Disease","enrollment":109},{"nctId":"NCT06604117","phase":"","title":"Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-10-17","conditions":"Ischemic Stroke, Atherosclerosis of Artery, Lipid Disorder","enrollment":200},{"nctId":"NCT06280976","phase":"PHASE4","title":"Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)","status":"WITHDRAWN","sponsor":"University of Louisville","startDate":"2024-03-01","conditions":"Coronary Artery Disease, Atherosclerosis, Heart Attack","enrollment":""},{"nctId":"NCT06784557","phase":"PHASE4","title":"Effect of Ezetimibe on Gut Microbiota","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2024-02-28","conditions":"Atherosclerotic Cardiovascular Disease With Dyslipidemia","enrollment":110},{"nctId":"NCT04656028","phase":"NA","title":"Genetic Testing and Motivational Counseling for FH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2020-06-15","conditions":"Hypercholesterolemia, Familial, Hypercholesterolemia, Familial, 1, Hypercholesterolemia, Familial, 2","enrollment":180},{"nctId":"NCT05930028","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2023-07-13","conditions":"Essential Hypertension, Primary Hypercholesterolemia","enrollment":148},{"nctId":"NCT04369664","phase":"PHASE4","title":"CHOlesterol Lowering and Residual Risk in Type 2 Diabetes","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-08-12","conditions":"Type 2 Diabetes","enrollment":151},{"nctId":"NCT04701242","phase":"NA","title":"Ezetimibe Utilization Early After Acute Myocardial Infarction, \"EzAMI Trial\"","status":"RECRUITING","sponsor":"Cairo University","startDate":"2021-03-24","conditions":"Acute Myocardial Infarction, Dyslipidemias","enrollment":500},{"nctId":"NCT00541697","phase":"PHASE3","title":"Eze/Simva Switch Study in Diabetics (0653A-807)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-19","conditions":"Diabetes Mellitus, Type 2","enrollment":648},{"nctId":"NCT00092638","phase":"PHASE3","title":"An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-05","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":450},{"nctId":"NCT00092625","phase":"PHASE3","title":"Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-03","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":442},{"nctId":"NCT00092716","phase":"PHASE3","title":"Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-05","conditions":"Hypercholesterolemia","enrollment":655},{"nctId":"NCT00132717","phase":"PHASE3","title":"A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-01","conditions":"Hypercholesterolemia","enrollment":450},{"nctId":"NCT00653796","phase":"PHASE4","title":"Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":148},{"nctId":"NCT00110435","phase":"PHASE3","title":"A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":"Type 2 Diabetes Mellitus, Hypercholesterolemia","enrollment":1229},{"nctId":"NCT00651378","phase":"PHASE4","title":"Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2004-09-01","conditions":"Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease","enrollment":87},{"nctId":"NCT00166530","phase":"PHASE4","title":"EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-11","conditions":"Atherosclerosis","enrollment":367},{"nctId":"NCT00090168","phase":"PHASE3","title":"Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-01-27","conditions":"Hypercholesterolemia, Atherosclerotic Disease, Coronary Disease","enrollment":435},{"nctId":"NCT00395603","phase":"PHASE3","title":"Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Cardiovascular Diseases, Diabetes Mellitus","enrollment":550},{"nctId":"NCT00157924","phase":"PHASE4","title":"Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-11","conditions":"Hypercholesterolemia","enrollment":190},{"nctId":"NCT00871351","phase":"PHASE4","title":"Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-02-01","conditions":"Primary Hypercholesterolemia","enrollment":125},{"nctId":"NCT00442897","phase":"PHASE4","title":"Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Hypercholesterolemia","enrollment":229},{"nctId":"NCT00166504","phase":"PHASE4","title":"Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-10","conditions":"Hypercholesterolemia","enrollment":203},{"nctId":"NCT00654095","phase":"PHASE3","title":"Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-12-01","conditions":"Hypercholesterolemia","enrollment":146},{"nctId":"NCT00496730","phase":"PHASE3","title":"A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-07","conditions":"Hypercholesterolemia","enrollment":256},{"nctId":"NCT00535405","phase":"PHASE3","title":"A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-11","conditions":"Hypercholesterolemia","enrollment":1289},{"nctId":"NCT02460159","phase":"PHASE3","title":"A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2015-06-23","conditions":"Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia","enrollment":135},{"nctId":"NCT00409773","phase":"PHASE3","title":"Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-01","conditions":"Hypercholesterolemia, Metabolic Syndrome","enrollment":1143},{"nctId":"NCT00782184","phase":"PHASE3","title":"Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-11","conditions":"Hypercholesterolemia","enrollment":250},{"nctId":"NCT02550288","phase":"PHASE3","title":"A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2015-09-29","conditions":"Hypercholesterolemia","enrollment":309},{"nctId":"NCT00462748","phase":"PHASE3","title":"A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-03","conditions":"Hypercholesterolemia","enrollment":786},{"nctId":"NCT00862251","phase":"PHASE3","title":"Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-04","conditions":"Cardiovascular Disorder, Diabetes Mellitus","enrollment":808},{"nctId":"NCT03768427","phase":"PHASE3","title":"Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2019-05-27","conditions":"Hypercholesterolemia","enrollment":454},{"nctId":"NCT00418834","phase":"PHASE3","title":"Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-01","conditions":"Hypercholesterolemia","enrollment":1053},{"nctId":"NCT00276484","phase":"PHASE3","title":"To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-02","conditions":"Hypercholesterolemia","enrollment":579},{"nctId":"NCT00276458","phase":"PHASE3","title":"To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-02","conditions":"Hypercholesterolemia","enrollment":196},{"nctId":"NCT03867110","phase":"PHASE3","title":"An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-03-06","conditions":"Hypercholesterolemia","enrollment":628},{"nctId":"NCT00092690","phase":"PHASE3","title":"MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-06","conditions":"Hypercholesterolemia","enrollment":1902},{"nctId":"NCT03882892","phase":"PHASE3","title":"Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-02-02","conditions":"Hypercholesterolemia","enrollment":400},{"nctId":"NCT03884452","phase":"PHASE3","title":"Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-05-03","conditions":"Familial Hypercholesterolemia","enrollment":50},{"nctId":"NCT03867318","phase":"PHASE3","title":"Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-04-24","conditions":"Hypercholesterolemia","enrollment":621},{"nctId":"NCT04968509","phase":"PHASE3","title":"Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2024-03-22","conditions":"Aortic Stenosis","enrollment":160},{"nctId":"NCT05365438","phase":"PHASE4","title":"Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia","status":"RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2022-10-01","conditions":"Dyslipidemias, Atherosclerosis, Diabetes Mellitus, Type 2","enrollment":105},{"nctId":"NCT05361421","phase":"PHASE4","title":"Effect of Intensive LDL-cholesterol Targeting for Elderly Patients With Cardiovascular Disease: I-OLD Trial","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2022-07-19","conditions":"Cardiovascular Disease","enrollment":1200},{"nctId":"NCT04900155","phase":"NA","title":"Evaluation of the Effect of Long-term Lipid-lowering Therapy in STEMI Patients With Coronavirus Infection COVID-19","status":"UNKNOWN","sponsor":"Penza State University","startDate":"2020-11-20","conditions":"STEMI, Covid19, NSTEMI","enrollment":45},{"nctId":"NCT04347434","phase":"PHASE4","title":"Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI","status":"RECRUITING","sponsor":"Penza State University","startDate":"2020-02-12","conditions":"Myocardial Infarction, Acute, Myocardial Strain, Arterial Stiffness","enrollment":300},{"nctId":"NCT05624658","phase":"NA","title":"Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS","status":"UNKNOWN","sponsor":"Samara Regional Cardiology Dispensary","startDate":"2022-09-02","conditions":"Dyslipidemias","enrollment":200},{"nctId":"NCT06096909","phase":"NA","title":"Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-11-01","conditions":"Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome","enrollment":3684},{"nctId":"NCT05970679","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2022-08-17","conditions":"Hypercholesterolemia, Dyslipidemia","enrollment":252},{"nctId":"NCT05705804","phase":"NA","title":"Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2023-06-13","conditions":"Dyslipidemias, Atherosclerotic Cardiovascular Disease","enrollment":250},{"nctId":"NCT03510884","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-31","conditions":"Hypercholesterolaemia","enrollment":153},{"nctId":"NCT05372380","phase":"PHASE1","title":"A Study to Evaluate Drug-drug Interactions Between BR1017-1 and BR1017-2 in Healthy Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2022-05-09","conditions":"Hypertension, Hypercholesterinemia","enrollment":32},{"nctId":"NCT04895098","phase":"","title":"Statin Monotherapy or Statins in Combination With Ezetimibe in Patients for Prevention of CVD","status":"COMPLETED","sponsor":"Akrikhin","startDate":"2021-06-23","conditions":"Lipid Metabolism Disorders, Cardiovascular Diseases","enrollment":1000},{"nctId":"NCT01763866","phase":"PHASE3","title":"LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-15","conditions":"Hyperlipidemia","enrollment":2067},{"nctId":"NCT01516879","phase":"PHASE3","title":"Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-01-05","conditions":"Hypercholesterolemia","enrollment":905},{"nctId":"NCT05131997","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2021-11-16","conditions":"Primary Hypercholesterolemia","enrollment":290},{"nctId":"NCT01047501","phase":"PHASE3","title":"Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":702},{"nctId":"NCT01047683","phase":"PHASE3","title":"Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":229},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT02476006","phase":"PHASE3","title":"Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-06-23","conditions":"Hypercholesterolemia","enrollment":998},{"nctId":"NCT00651404","phase":"PHASE3","title":"Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":137},{"nctId":"NCT03885921","phase":"PHASE3","title":"Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-10-25","conditions":"Hypercholesterolemia","enrollment":44},{"nctId":"NCT00650689","phase":"PHASE3","title":"Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-05","conditions":"Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease","enrollment":122},{"nctId":"NCT03882996","phase":"PHASE3","title":"A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-10-06","conditions":"Hypercholesterolemia","enrollment":432},{"nctId":"NCT00202904","phase":"PHASE4","title":"Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":"Hypercholesterolemia, Coronary Heart Disease","enrollment":81},{"nctId":"NCT01236430","phase":"PHASE1","title":"A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-02","conditions":"Hyperlipidemia","enrollment":200},{"nctId":"NCT00319449","phase":"PHASE4","title":"Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09","conditions":"Hypercholesterolemia, Coronary Arteriosclerosis","enrollment":22},{"nctId":"NCT00730132","phase":"","title":"Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-01","conditions":"Coronary Heart Disease, Hypercholesterolemia","enrollment":712},{"nctId":"NCT01370603","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-09","conditions":"Hypercholesterolemia","enrollment":328},{"nctId":"NCT01154036","phase":"PHASE3","title":"MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-07","conditions":"Hypercholesterolemia","enrollment":1547},{"nctId":"NCT01370590","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-09","conditions":"Hypercholesterolemia","enrollment":406},{"nctId":"NCT00652327","phase":"PHASE4","title":"Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Hypercholesterolemia","enrollment":83},{"nctId":"NCT03355027","phase":"NA","title":"Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-11-30","conditions":"Atherosclerosis, Cardiovascular Diseases","enrollment":60},{"nctId":"NCT04829149","phase":"","title":"Statin Monotherapy and Rosuzet Tab.(Rosuvastatin/Ezetimibe) Administration in Patients With Dyslipidemia in Korea","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2016-06-14","conditions":"Dyslipidemias","enrollment":5717},{"nctId":"NCT03877783","phase":"NA","title":"DEMAND - Multifactorial Study to Reduce Dementia in People With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Umeå University","startDate":"2020-10-19","conditions":"Type 2 Diabetes Mellitus, Mild Cognitive Impairment","enrollment":10},{"nctId":"NCT04737408","phase":"PHASE3","title":"Influence of Intensive Lipid-lowering on FFRCT (The FLOW-PROMOTE Study)","status":"UNKNOWN","sponsor":"Bjarne Linde Noergaard","startDate":"2020-05-13","conditions":"Coronary Artery Disease","enrollment":120},{"nctId":"NCT03510715","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-31","conditions":"Hypercholesterolemia","enrollment":18},{"nctId":"NCT02767362","phase":"EARLY_PHASE1","title":"A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2015-11","conditions":"Endometrial Cancer","enrollment":24},{"nctId":"NCT04455581","phase":"PHASE2","title":"A Study to Determine the Safety, Tolerability, and Efficacy of SHR-1209 in Patients With Familial Hypercholesterolemia","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-09-01","conditions":"Familial Hypercholesterolemia","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Atorvastatin, Ezetimibe","genericName":"Atorvastatin, Ezetimibe","companyName":"Abant Izzet Baysal University","companyId":"abant-izzet-baysal-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atorvastatin inhibits HMG-CoA reductase to lower LDL cholesterol, while ezetimibe blocks intestinal cholesterol absorption, providing dual lipid-lowering action. Used for Hypercholesterolemia and dyslipidemia, Cardiovascular disease risk reduction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}